Surface Dilational Rheology, Foam, and Core Flow Properties of Alpha Olefin Sulfonate
Abstract The surface tension, surface dilational rheology, foaming and displacement flow properties of alpha olefin sulfonate (AOS) with inorganic salts were studied. The foam composite index (FCI), which reflects foaming capacity and foam stability, is used to evaluate foam properties. It is found that sodium and calcium salts can lead to decreases in AOS surface tension, critical micelle concentration, and molecular area at the gas–liquid interface. Sodium ions reduce the surface dilational viscoelasticity (E) and FCI of AOS, while calcium ions can enhance the E of AOS and make the FCI of AOS reach a maximum. In the solution containing calcium and sodium ions, the FCI of AOS is improved. Crude oil reduces the FCI of AOS. Injection pressure and displacing efficiency of AOS alternating carbon dioxide ($ CO_{2} $) injection are higher than injections of water alternating with $ CO_{2} $ or $ CO_{2} $ alone in low permeability cores..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Journal of surfactants and detergents - 20(2016), 1 vom: 19. Okt., Seite 35-45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Hongsheng [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Alpha olefin sulfonate |
| Anmerkungen: |
© AOCS 2016 |
|---|
| doi: |
10.1007/s11743-016-1889-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2073235727 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2073235727 | ||
| 003 | DE-627 | ||
| 005 | 20230304072522.0 | ||
| 007 | tu | ||
| 008 | 200819s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11743-016-1889-5 |2 doi | |
| 035 | |a (DE-627)OLC2073235727 | ||
| 035 | |a (DE-He213)s11743-016-1889-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 58.28$jPharmazeutische Technologie |2 bkl | ||
| 100 | 1 | |a Liu, Hongsheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surface Dilational Rheology, Foam, and Core Flow Properties of Alpha Olefin Sulfonate |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © AOCS 2016 | ||
| 520 | |a Abstract The surface tension, surface dilational rheology, foaming and displacement flow properties of alpha olefin sulfonate (AOS) with inorganic salts were studied. The foam composite index (FCI), which reflects foaming capacity and foam stability, is used to evaluate foam properties. It is found that sodium and calcium salts can lead to decreases in AOS surface tension, critical micelle concentration, and molecular area at the gas–liquid interface. Sodium ions reduce the surface dilational viscoelasticity (E) and FCI of AOS, while calcium ions can enhance the E of AOS and make the FCI of AOS reach a maximum. In the solution containing calcium and sodium ions, the FCI of AOS is improved. Crude oil reduces the FCI of AOS. Injection pressure and displacing efficiency of AOS alternating carbon dioxide ($ CO_{2} $) injection are higher than injections of water alternating with $ CO_{2} $ or $ CO_{2} $ alone in low permeability cores. | ||
| 650 | 4 | |a Alpha olefin sulfonate | |
| 650 | 4 | |a Surface tension | |
| 650 | 4 | |a Surface dilational viscoelasticity | |
| 650 | 4 | |a Foam composite index | |
| 650 | 4 | |a Low permeability cores | |
| 700 | 1 | |a Han, Peihui |4 aut | |
| 700 | 1 | |a Sun, Gang |4 aut | |
| 700 | 1 | |a Pan, Feng |4 aut | |
| 700 | 1 | |a Li, Bo |4 aut | |
| 700 | 1 | |a Wang, Jingqin |4 aut | |
| 700 | 1 | |a Lv, Changsen |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of surfactants and detergents |d Springer Berlin Heidelberg, 1998 |g 20(2016), 1 vom: 19. Okt., Seite 35-45 |w (DE-627)265185416 |w (DE-600)1465201-8 |w (DE-576)272962937 |x 1097-3958 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2016 |g number:1 |g day:19 |g month:10 |g pages:35-45 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11743-016-1889-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_2018 | ||
| 936 | b | k | |a 58.28$jPharmazeutische Technologie |q VZ |0 106417622 |0 (DE-625)106417622 |
| 951 | |a AR | ||
| 952 | |d 20 |j 2016 |e 1 |b 19 |c 10 |h 35-45 | ||